Sangamo Therapeutics, Inc. (SGMO) Earnings History
Annual and quarterly earnings data from 1999 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -179.9% | -169.4% |
| 2023 | 100.0% | -155.5% | -146.3% |
| 2022 | 89.1% | -180.8% | -172.8% |
| 2021 | 100.0% | -165.6% | -161.1% |
| 2020 | -52.8% | -109.6% | -102.4% |
Download Data
Export SGMO earnings history in CSV or JSON format
Free sign-in required to download data
Sangamo Therapeutics, Inc. (SGMO) Earnings Overview
As of March 2, 2026, Sangamo Therapeutics, Inc. (SGMO) reported trailing twelve-month net income of -$109M, reflecting +0.7% year-over-year growth. The company earned $-0.36 per diluted share over the past four quarters, with a net profit margin of -1.7%.
Looking at the long-term picture, SGMO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 1999.
Sangamo Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), IONS (-$381M net income, -0.4% margin), ARWR ($202M net income, -0.0% margin), SGMO has room to improve margins relative to the peer group. Compare SGMO vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
26 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$98M | +62.0% | -$104M | $-0.49 | -169.4% | -179.9% |
| 2023 | -$258M | -34.1% | -$274M | $-1.48 | -146.3% | -155.5% |
| 2022 | -$192M | -7.8% | -$201M | $-1.25 | -172.8% | -180.8% |
| 2021 | -$178M | -47.3% | -$183M | $-1.23 | -161.1% | -165.6% |
| 2020 | -$121M | -27.1% | -$130M | $-0.90 | -102.4% | -109.6% |
| 2019 | -$95M | -39.3% | -$105M | $-0.68 | -92.9% | -102.7% |
| 2018 | -$68M | -25.2% | -$77M | $-0.70 | -80.9% | -91.4% |
| 2017 | -$55M | +23.8% | -$56M | $-0.70 | -149.2% | -154.1% |
| 2016 | -$72M | -76.1% | -$73M | $-1.02 | -369.6% | -374.2% |
| 2015 | -$41M | -54.1% | -$47M | $-0.58 | -102.9% | -118.5% |
See SGMO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SGMO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SGMO vs AGIO
See how SGMO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SGMO growing earnings?
SGMO EPS of $-0.36 reflects slowing growth at +0.7%, below the 5-year CAGR of N/A. TTM net income is $-109M. Expansion rate has moderated.
What are SGMO's profit margins?
Sangamo Therapeutics, Inc. net margin is -1.7%, with operating margin at -1.8%. Below-average margins reflect competitive or cost pressures.
How consistent are SGMO's earnings?
SGMO earnings data spans 1999-2024. The current earnings trend is +0.7% YoY. Historical data enables comparison across business cycles.